RNS Number : 7885C
N4 Pharma PLC
19 June 2019

19 June 2019

N4 Pharma Plc
("**N4 Pharma**" or the "**Company**")

Result of AGM

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. All resolutions were passed on a show of hands. The results of the proxy voting for the AGM is set out below.

	Resolution	*Total votes For*[1]	*% of votes cast*[2]	*Total Votes Against*	*% of votes cast*[2]	*Total Votes Cast*[3]	*% of issued share capital*	*Votes Withheld*[4]
1	To receive the annual report and audited accounts for the year ended 31 December 2018	16,362,457	99.99	1,134	0.01	16,363,591	16.13	0
2	To re-elect Luke Cairns as a director of the Company	16,332,857	99.99	1,134	0.01	16,333,991	16.10	29,600
3	To elect John Chiplin as a Director of the Company	16,332,857	99.99	1,134	0.01	16,333,991	16.10	29,600
4	To elect Chris Britten as a Director of the Company	16,332,857	99.99	1,134	0.01	16,333,991	16.10	29,600
5	To re-appoint Saffery Champness LLP as auditor and authorise directors to determine	16,334,857	99.85	25,000	0.15	16,359,857	16.12	3,734

	their remuneration							
6	Authority to allot shares	16,331,657	99.82	30,200	0.18	16,361,857	16.12	1.734
7	Authority to disapply pre-emption rights	16,330,457	99.97	5,334	0.03	16,335,791	16.10	27,800

Notes:

1. Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Total Votes Cast do not include withheld votes
4. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution

Enquiries:

N4 Pharma Plc
Nigel Theobald, CEO — Via Scott PR

Allenby Capital Limited — Tel: +44(0)203 328 5656
James Reeve/Asha Chotai

Scott PR
Georgia Smith — Tel: +44(0)1477 539 539

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGBBGDLGUBBGCC